Carlsmed initiated with an Overweight at Piper Sandler

Piper Sandler analyst Matt O’Brien initiated coverage of Carlsmed (CARL) with an Overweight rating and $18 price target The company 3D-printed spinal implants that are custom fit to each patient’s anatomy and is currently the only one of its kind on the market, the analyst tells investors in a research note. The firm believes the capital from the initial public offering will Carlsmed with its sales force expansion efforts, driving further surgeon adoption and market penetration.